Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 24

Trial readouts

UK tirzepatide price rise shifted use

A million-person UK cohort linked a tirzepatide price increase with more semaglutide starts and treatment switching in self-paying care.

16 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 addiction study has no results yet

A planned semaglutide study will track addiction and social outcomes in 1,200 people, but it has no participant results or public protocol yet.

15 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Hair Loss Review: What It Found

A 2026 GLP-1 hair loss review links shedding mainly to weight change, but the narrative evidence cannot prove direct drug causation.

15 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Drugs and Spine Surgery Outcomes

A 23-study systematic review found procedure-specific, mostly observational associations rather than a clear benefit or harm in spine surgery.

15 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 Drugs and Substance Use Evidence

A 2026 review maps early semaglutide, exenatide, alcohol and tobacco findings without establishing incretin drugs as addiction treatments.

15 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Drugs Cut Test-Meal Intake

A 2026 meta-analysis found GLP-1 therapy reduced intake by about 271 kcal at one test lunch, with real-world diet effects still uncertain.

15 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Receptor Binding in Simulations

A 2026 computational study compared four GLP-1 receptor complexes, finding persistent structural differences without testing clinical outcomes.

15 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Oral Semaglutide: 4-Month Study

A 70-person observational study linked four months of oral semaglutide care with lower weight, mostly through reduced fat mass.

15 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Pediatric Obesity Drug Review: Gaps

A 2026 pediatric obesity drug review links adolescent semaglutide evidence with adult retatrutide research while leaving long-term safety open.

15 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Gait Speed in Semaglutide-Inclusive Care

A 22-person observational study found faster gait after multidisciplinary obesity care but cannot isolate a semaglutide effect.

15 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

SURPASS-CVOT Heart Failure Analysis

An exploratory SURPASS-CVOT analysis compared tirzepatide and dulaglutide outcomes by prior heart-failure history.

15 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Adolescent GLP-1 Review: Evidence Gaps

A 2026 review finds short-term benefits from adolescent GLP-1 therapy but major gaps around growth, puberty, cognition and lifelong effects.

14 Oct 2026 · PeptideMethods Editorial Team · 4 min read